Trials / Completed
CompletedNCT01969643
A Safety Study of SGN-LIV1A in Breast Cancer Patients
A Phase 1, Open-Label, Dose-Escalation Study to Evaluate the Safety and Tolerability of SGN-LIV1A in Patients With Metastatic Breast Cancer
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 290 (actual)
- Sponsor
- Seagen Inc. · Industry
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study will examine the safety and tolerability of ladiratuzumab vedotin (LV) in patients with metastatic breast cancer. LV will be given alone or in combination with trastuzumab.
Conditions
- HER2 Positive Breast Neoplasms
- Hormone Receptor Positive Breast Neoplasms
- Triple Negative Breast Neoplasms
- HER2 Mutations Breast Neoplasms
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ladiratuzumab vedotin | LV will be given into the vein (IV; intravenously) |
| DRUG | Trastuzumab | Trastuzumab will be given by IV every 3 weeks at a dose of 6 mg/kg (the first dose will be 8 mg/kg) |
Timeline
- Start date
- 2013-10-22
- Primary completion
- 2023-02-04
- Completion
- 2023-02-04
- First posted
- 2013-10-25
- Last updated
- 2023-03-07
Locations
38 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT01969643. Inclusion in this directory is not an endorsement.